Mark J. Holterman, Medical

21st Century Cures Act Supports Regenerative Medicine


21st Century Cures Act pic
21st Century Cures Act

Mark Holterman, MD, a pediatric surgeon, has served as a member of the general surgical team at Children’s Hospital at OSF Healthcare since 2011. He is additionally a professor in the Division of Pediatric Surgery at the University of Illinois College of Medicine in Peoria. Dr. Mark Holterman, CEO of regenerative medicine-focused Mariam Global Health, maintains a strong interest in the development of cell-based therapies.

In late 2016, the United States Congress passed and President Obama signed the 21st Century Cures Act. This legislation, the result of bi-partisan alliances in Congress, was designed to help patients with serious health conditions benefit from the fast-tracking of new drugs and medical devices. It also channels new funds into medical research. In addition to its $2 billion designated over a two-year period to fight the American opioid epidemic, and other provisions, the law provides greater support to the field of regenerative medicine.

The act builds on the Food and Drug Administration’s recent practice of incorporating the input of patients into the agency’s drug approval procedures. Thus, it provides for a quicker and more efficient FDA approval process for certain stem cell treatments before they enter the market. The membership of groups such as the World Stem Cell Summit and the Alliance for Regenerative Medicine applauded the new legislation.

Mark J. Holterman, Medical

ADA and APA Join Hands in Training Mental Health Professionals


ADA and APA  pic

Mark Holterman, MD received his degree in medicine and immunology from the University of Virginia. He currently serves as a professor of surgery and pediatrics at the University of Illinois College of Medicine. Dr. Mark Holterman is a member of several professional organizations including the American Diabetes Association (ADA).

Founded in 1940, ADA is a leading non-profit organization that concentrates on conducting research, education, and advocacy activities related to the treatment, prevention, and cure of diabetes. The organization sponsors several programs to support its mission, some of which are collaborative efforts with other organization. One of these programs is the Mental Health Provider Diabetes Education Program, a joint effort with the American Psychological Association.

The program aims to serve the need for mental health professionals who are willing to cater to the psychosocial challenges associated with diabetes management. It is a two-part continuing education program that requires interested practitioners to complete a seven-hour face-to-face seminar and a five-hour online course. Upon successful completion of the courses, providers will be listed on the ADA website which can be freely accessed by those seeking treatment. This program launched in June of this year and has recently received a $839-million grant from the Helmsley Charitable Trust.

Mark J. Holterman, Medical

Treatment Goals for SJIA


Dr. Mark J. Holterman pic
Dr. Mark J. Holterman

Yale University alumnus Mark Holterman, MD is a successful pediatrician and surgeon with over two decades of experience. He currently holds a full professorship position at the University of Illinois College of Medicine where he is an active surgeon inthe division of pediatric surgery. Dr. Mark Holterman was one of the minds behind the establishment of non-profit organization The Hannah Sunshine Foundation.

The Hannah Sunshine Foundation is an organization that focuses on the use of cellular and regenerative therapies for children with rare diseases. It was inspired by three young people, one of which was Sarah Hughes, a 23-year-old woman afflicted with systemic juvenile idiopathic arthritis (SJIA).

SJIA is a serious subtype of juvenile idiopathic arthritis (JIA). Unlike other types of JIA, the condition not only affects the joints but also involves other organs such as the heart, liver, and lungs. The condition is rare and only occurs among 10 to 20 percent of all children who have some form of JIA.

The disease has no known cure as of yet, but treatment is available. Doctors managing the disease focus on achieving permanent remission – a state wherein there are no clinical signs and symptoms that the disease is still active. Due to the damage that it may bring the joints, experts believe that early, aggressive treatment during the active phase of the disease should be encouraged.